Back to top

Halozyme Buy Rating Reiterated as VYVGART Hytrulo Data Support Royalty Growth; $115 Price Target Unchanged

In a report released today, Mitchell Kapoor from H.C. Wainwright reiterated a Buy rating on Halozyme, with a price target of $115.00. Mitchell Kapo...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Halozyme Therapeutics, Inc. (HALO)